Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onivyde

- PMLiVE

HIV prevention pill heads July CHMP recommendations

Gilead’s Truvada given positive opinion alongside Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx

- PMLiVE

Ipsen searches for new CEO after splitting top roles

Structural reshuffle aimed at accelerating international development

- PMLiVE

Servier announces job cuts as pressures mount

Frenchpharma firm to let go of 610 workers

- PMLiVE

Cellectis gets big pharma partners for CAR-T therapy

Pfizer, Servier and Cellectis in three-way deal to develop CAR-T immunotherapy

- PMLiVE

FDA approves Merrimack’s pancreatic cancer drug

Onivyde improves overall survival rates

- PMLiVE

Ipsen acquires OctreoPharm to boost its oncology presence

Will aid the development of its approach to neuroendrocrine tumours

- PMLiVE

IMI picks Ipsen’s Marc de Garidel to chair governing board

He takes over from former UCB CEO Roch Doliveux

France flag

French pharma growth restricted by generics

New analysis finds country’s market value will grow only modestly in the coming years

- PMLiVE

FDA approves Ipsen drug to treat rare tumours

Green light for Somatuline Depot in cancer of the neuroendocrine system

- PMLiVE

Servier licenses device that could ‘reshape’ diabetes care

Tiny pump implant to deliver GLP-1 agonist

- PMLiVE

Servier abandons cancer drug collaboration with Pharmacyclics

Rights to lymphoma treatment abexinostat will be returned

- PMLiVE

Servier signs cancer collaboration with Cellectis

Will target leukaemia and five solid tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links